Palvella Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Palvella Therapeutics, Inc. (PVLA) reported Revenue from Contract with Customer, Excluding Assessed Tax of $43.65 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-13.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2020-03-13
- Palvella Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2019-12-31 was $16.68M, a 254.37% increase year-over-year.
- Palvella Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2019-09-30 was $14.50M, a 84.15% increase year-over-year.
- Palvella Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2019-06-30 was $4.93M, a 56.04% decline year-over-year.
- Palvella Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2019-03-31 was $7.53M, a 118.76% increase year-over-year.
- Palvella Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $43.65M, a 60.18% increase from fiscal 2018.
- Palvella Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2018 was $27.25M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2019-12-31 | $16.68M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $31.18M derived: sum of 2 quarters · filed 2020-03-13 | $36.11M derived: sum of 3 quarters · filed 2020-03-13 | $43.65M 10-K · filed 2020-03-13 |
| 2019-09-30 | $14.50M 10-Q · filed 2019-11-12 | $19.43M derived: sum of 2 quarters · filed 2019-11-12 | $26.97M 10-Q · filed 2019-11-12 | $31.67M derived: sum of 4 quarters · filed 2020-03-13 |
| 2019-06-30 | $4.93M 10-Q · filed 2019-08-09 | $12.47M 10-Q · filed 2019-08-09 | $17.18M derived: sum of 3 quarters · filed 2020-03-13 | $25.05M derived: sum of 4 quarters · filed 2020-03-13 |
| 2019-03-31 | $7.53M 10-Q · filed 2019-05-10 | $12.24M derived: sum of 2 quarters · filed 2020-03-13 | $20.11M derived: sum of 3 quarters · filed 2020-03-13 | $31.34M derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-12-31 | $4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $12.58M derived: sum of 2 quarters · filed 2020-03-13 | $23.80M derived: sum of 3 quarters · filed 2020-03-13 | $27.25M 10-K · filed 2020-03-13 |
| 2018-09-30 | $7.87M 10-Q · filed 2019-11-12 | $19.10M derived: sum of 2 quarters · filed 2019-11-12 | $22.54M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $11.22M 10-Q · filed 2019-08-09 | $14.67M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $3.44M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |